Who would have thought that an ancient Chinese herbal remedy would one day become the panacea for malaria? Sweet wormwood (Artemisia annua) was indeed used in traditional Chinese medicine for more than 2 000 …
- Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary
- New Kisqali (ribociclib)* overall survival data from extended follow-up of MONALEESA-3 trial in patients with postmenopausal HR+/HER2- advanced or metastatic breast cancer
- Phase II results for oral, targeted factor B inhibitor iptacopan (LNP023) as first line monotherapy in …
- Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needs
- Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, Spain expands for sterile active pharmaceutical ingredients
- Investment affirms long-term confidence in antibiotics strategy, delivering and building on published plans for European-based manufacturing network
Basel, May 18, 2021 — …
- Novartis has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999
- With other innovations, the Novartis artemisinin-based combination therapy (ACT) contributed to reduce malaria deaths by nearly half over the same timeframe1
- Novartis continues to invest in research and development for next-generation antimalarials to combat the threat of artemisinin resistance
The digital press …
- Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients
- Sandoz is disappointed US patients affected by chronic autoimmune and inflammatory disease have to wait until 2029 for availability of biosimilar Erelzi
- Sandoz remains committed to pioneering access for patients and contributing to more …
Today is World Asthma Day, when people across the asthma community come together to raise awareness of the challenges being faced by millions of people living with asthma, their families, friends and caregivers. Asthma is a common condition, affecting approximately …
Amid the coronavirus pandemic, concern has grown over the potential neglect of other serious diseases. Multiple sclerosis (MS), for example, is a condition for which timely diagnosis, early treatment and the development of innovative therapies are particularly important for reducing the disabling progress of the disease. MS is the most common auto immune disorder to affect the central nervous system – that is, the brain and spinal cord. In many patients, the symptoms cause serious distress, increasingly diminishing their quality of life as their disability worsens. The average age of onset …
“I’m not letting you leave my office with that on your back.”
Jordan remembers her dermatologist’s words at the appointment that changed her life. At just 20 years old, she was diagnosed with advanced, stage III melanoma.
“Why me? I was too young to get skin cancer,” she remembers thinking. “I felt that I had done everything I could to limit my risk of skin cancer.”
But Jordan soon learned that while skin protection is important, skin cancer and melanoma can’t always be prevented.
Melanoma is the most serious and life-threatening type of skin cancer, but it is …
- Sandoz to begin enrolling patients with neovascular age-related macular degeneration in MYLIGHT Phase lll confirmatory efficacy and safety study1
- Neovascular age-related macular degeneration accounts for 10% of age-related macular degeneration cases, but is responsible for 90% of AMD-related blindness2
- With eight marketed biosimilar medicines globally and 15+ molecules in pipeline, Sandoz is investing in future of biosimilars for patients and healthcare systems
…
- In KESTREL and KITE, Beovu (brolucizumab) 6 mg met the primary endpoints of non-inferiority in change in best corrected visual acuity from baseline versus aflibercept 2 mg at year one in diabetic macular edema (DME) patients1
- More patients treated with Beovu 6 mg experienced fluid (IRF/SRF) resolution at week 32 and week 52 versus aflibercept; fluid is a key marker of disease activity in DME1
- Beovu demonstrated an overall well-tolerated safety profile in KESTREL and KITE …